Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis

PurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jörg Tamihardja, Paul Lutyj, Johannes Kraft, Dominik Lisowski, Stefan Weick, Michael Flentje, Bülent Polat
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	prostate cancer high-dose-rate (HDR) brachytherapy radiotherapy long-term outcome toxicity external beam radiotherapy (EBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0321cd8052c44919a1ba36bafc7c7a1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0321cd8052c44919a1ba36bafc7c7a1e
record_format	dspace
spelling	oai:doaj.org-article:0321cd8052c44919a1ba36bafc7c7a1e2021-12-01T04:16:37ZTwo-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis2234-943X10.3389/fonc.2021.764536https://doaj.org/article/0321cd8052c44919a1ba36bafc7c7a1e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.764536/fullhttps://doaj.org/toc/2234-943XPurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-BT boost) in the period of 2002 to 2019 were analyzed. EBRT, delivered in 46 Gy (DMean) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D90%) two and four weeks after EBRT. Androgen deprivation therapy (ADT) was added in 176 (52.1%) patients. Genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated utilizing the Common Toxicity Criteria for Adverse Events (version 5.0) and biochemical failure was defined according to the Phoenix definition.ResultsMedian follow-up was 101.8 months. 15 (4.4%)/115 (34.0%)/208 (61.5%) patients had low-/intermediate-/high-risk cancer according to the D`Amico risk classification. Estimated 5-year and 10-year biochemical relapse-free survival (bRFS) was 84.7% and 75.9% for all patients. The estimated 5-year bRFS was 93.3%, 93.4% and 79.5% for low-, intermediate- and high-risk disease, respectively. The estimated 10-year freedom from distant metastasis (FFM) and overall survival (OS) rates were 86.5% and 70.0%. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥ 2 was observed in 19.3% and 5.0% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in 3.6%/0.3%.ConclusionsTwo-weekly HDR-BT boost after EBRT for localized prostate cancer showed an excellent toxicity profile with low GU/GI toxicity rates and effective long-term biochemical control.Jörg TamihardjaPaul LutyjJohannes KraftDominik LisowskiStefan WeickMichael FlentjeBülent PolatFrontiers Media S.A.articleprostate cancerhigh-dose-rate (HDR) brachytherapyradiotherapylong-term outcometoxicityexternal beam radiotherapy (EBRT)Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer high-dose-rate (HDR) brachytherapy radiotherapy long-term outcome toxicity external beam radiotherapy (EBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prostate cancer high-dose-rate (HDR) brachytherapy radiotherapy long-term outcome toxicity external beam radiotherapy (EBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jörg Tamihardja Paul Lutyj Johannes Kraft Dominik Lisowski Stefan Weick Michael Flentje Bülent Polat Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
description	PurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-BT boost) in the period of 2002 to 2019 were analyzed. EBRT, delivered in 46 Gy (DMean) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D90%) two and four weeks after EBRT. Androgen deprivation therapy (ADT) was added in 176 (52.1%) patients. Genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated utilizing the Common Toxicity Criteria for Adverse Events (version 5.0) and biochemical failure was defined according to the Phoenix definition.ResultsMedian follow-up was 101.8 months. 15 (4.4%)/115 (34.0%)/208 (61.5%) patients had low-/intermediate-/high-risk cancer according to the D`Amico risk classification. Estimated 5-year and 10-year biochemical relapse-free survival (bRFS) was 84.7% and 75.9% for all patients. The estimated 5-year bRFS was 93.3%, 93.4% and 79.5% for low-, intermediate- and high-risk disease, respectively. The estimated 10-year freedom from distant metastasis (FFM) and overall survival (OS) rates were 86.5% and 70.0%. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥ 2 was observed in 19.3% and 5.0% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in 3.6%/0.3%.ConclusionsTwo-weekly HDR-BT boost after EBRT for localized prostate cancer showed an excellent toxicity profile with low GU/GI toxicity rates and effective long-term biochemical control.
format	article
author	Jörg Tamihardja Paul Lutyj Johannes Kraft Dominik Lisowski Stefan Weick Michael Flentje Bülent Polat
author_facet	Jörg Tamihardja Paul Lutyj Johannes Kraft Dominik Lisowski Stefan Weick Michael Flentje Bülent Polat
author_sort	Jörg Tamihardja
title	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
title_short	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
title_full	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
title_fullStr	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
title_full_unstemmed	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
title_sort	two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy for localized prostate cancer: long-term outcome and toxicity analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0321cd8052c44919a1ba36bafc7c7a1e
work_keys_str_mv	AT jorgtamihardja twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT paullutyj twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT johanneskraft twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT dominiklisowski twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT stefanweick twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT michaelflentje twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis AT bulentpolat twoweeklyhighdoseratebrachytherapyboostafterexternalbeamradiotherapyforlocalizedprostatecancerlongtermoutcomeandtoxicityanalysis
_version_	1718405882430095360

Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis

Ejemplares similares